Adenosine A_2A Receptor Antagonists for Cancer Immunotherapy

Area of Science:

• Oncoimmunology
• Pharmacology
• Molecular Biology

Background:

• Immune checkpoint blockade has transformed cancer therapy.
• Adenosine receptors (A_2AR and A_2BR) are emerging as critical regulators of the tumor microenvironment's immunosuppressive activity.

Purpose of the Study:

• To review the immunosuppressive roles of adenosine A_2A receptor (A_2AR) and A_2BR in the tumor microenvironment.
• To summarize the structure-activity relationships (SAR) of A_2AR and dual A_2AR/A_2BR antagonists with demonstrated oncoimmunological effects.

Main Methods:

• Literature review of existing studies on adenosine receptor antagonists in cancer.
• Analysis of structure-activity relationships for compounds targeting A_2AR and A_2BR.
• Examination of clinical trial data for relevant compounds.

Main Results:

• A_2AR and A_2BR play significant immunosuppressive roles within the tumor microenvironment.
• Several antagonists targeting A_2AR and dual A_2AR/A_2BR have shown promising oncoimmunological effects.
• Insights into ligand binding modes and ongoing clinical evaluations are provided.

Conclusions:

• Targeting adenosine A_2AR and A_2BR represents a viable strategy for novel cancer immunotherapies.
• Further development of A_2AR and dual A_2AR/A_2BR antagonists holds potential for clinical success in cancer treatment.